Covidien to Buy Back Shares and 3 Stocks At 52-Week Highs

Acadia Pharmaceuticals (NASDAQ:ACAD): Closing price $8.24

ACADIA has presented detailed results from it’s pivotal Phase III -020 Study with pimavanserin in patients suffering from Parkinson’s disease psychosis. The analysis of the full data set from the Phase III -020 Study indicated robust and consistent efficacy of pimavanserin throghout a wide array of study measures and confirmed the positive top-line results previously reported. Pimavanserin met the primary endpoint in the -020 Study by showing highly significant antipsychotic efficacy on the 9-item SAPS-PD scale. Pimavanserin also attained the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson’s Disease Rating Scale, or UPDRS. Shares closed up 23.91 percent on Thursday at $8.24, up $1.59 or 23.91% on the day. They have traded in a 52-week range of $1.29 to $6.88.